Figure 3.

Circulating CD8+ NKs were a prognostic value for predicting the response to treatment and overall survival of R/R DLBCL patients. (A). ROC curve analyses of both subsets of NKs at baseline for the prognosis of treatment response in R/R DLBCL patients. (B). Kaplan–Meier curves of overall survival according to the levels of circulating CD8+ NKs and CD8- NKs in R/R DLBCL patients. (C). Levels of CD8+ NKs and CD8- NKs in patients with OS >24 months and OS <24 months. (D). Cox-regression analysis of CD8 NK cells subpopulations and primary refractory disease in patients. For all the analyses, *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001 and ****P ≤ 0.0001. ns, not significant.